Keryx Biopharmaceuticals, Inc. (KERX) Posts Q3 Loss of $0.15
Tweet
Share
E-mailGet Alerts KERX Hot Sheet
Join SI Premium – FREE
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) reported Q3 EPS of ($0.15), $0.03 worse than the analyst estimate of ($0.12).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
- Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
